Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Osiris Therapeutics, Inc.    OSIR   US68827R1086

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/18/2015 05/19/2015 05/20/2015 05/21/2015 05/22/2015 Date
17.78(c) 18.23(c) 18.5(c) 18.36(c) 18.2(c) Last
148 571 233 946 146 508 169 772 193 622 Volume
+2.83% +2.53% +1.48% -0.76% -0.87% Change
More quotes
Financials ($)
Sales 2015 102 M
EBIT 2015 16,8 M
Net income 2015 14,2 M
Debt 2015 -
Yield 2015 -
Sales 2016 127 M
EBIT 2016 26,6 M
Net income 2016 23,2 M
Debt 2016 -
Yield 2016 -
PER 2015 44,94
PER 2016 28,22
Capi. / Sales 2015 6,15x
Capi. / Sales 2016 4,94x
Capitalization 626 M
More Financials
Company
Osiris Therapeutics, Inc. is a stem cell company, which focuses on developing and marketing products to treat medical conditions in the inflammatory, cardiovascular and wound healing markets.The company operates its business through two segments: Therapeutics and Biosurgery segment.The Therapeutics... 
More about the company
Surperformance© ratings of Osiris Therapeutics, Inc.
Trading Rating : - Investor Rating :
More Ratings
Latest news on OSIRIS THERAPEUTICS, INC.
05/21 OSIRIS THERAPEUTICS : Evaluates the Establishment of an International Subsidiary
05/21 OSIRIS THERAPEUTICS : Evaluates the Establishment of an International Subsidiary
05/14 OSIRIS THERAPEUTICS : Posts 1Q 2015 Financial Results
05/13 OSIRIS THERAPEUTICS : Posts First Quarter 2015 Financial Results
05/11 OSIRIS THERAPEUTICS : Management's Discussion and Analysis of Financial Conditio..
05/08 OSIRIS THERAPEUTICS : posts 1Q profit
05/08 OSIRIS THERAPEUTICS : Announces First Quarter 2015 Financial Results
05/08 OSIRIS THERAPEUTICS : Results of Operations and Financial Condition, Financial S..
More news
Sector news : Bio Therapeutic Drugs
05/22 SYNAGEVA BIOPHARMA : SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investiga..
05/22 BLUEBIRD BIO : Announces Participation at the Jefferies 2015 Global Healthcare C..
05/21 ABBVIE : specifies breakdown of $21 billion Pharmacyclics deal
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
05/13 TiGenix's Phase 3 Trial Of Allogeneic Stem Cells Is Likely To Succeed
05/09 Legal Trouble May Be Coming For Osiris' Sales Executives
05/08 Osiris Therapeutics' (OSIR) CEO Lode Debrabandere on Q1 2015 Results - Earnin..
05/08 Osiris Therapeutics earnings up 333% in Q1
05/08 Osiris Therapeutics beats by $0.04, beats on revenue


Comments 
Advertisement
Chart OSIRIS THERAPEUTICS, INC.
Duration : Period :
Osiris Therapeutics, Inc. Technical Analysis Chart | OSIR | US68827R1086 | 4-Traders
Full-screen chart
Technical analysis trends
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions